Company Overview of Opsona Therapeutics Ltd.
Opsona Therapeutics Ltd. operates as an innate immune drug development company. It specializes in novel therapeutic and preventative approaches to autoimmune and inflammatory diseases. The company’s products include OPN-305, a compound to reduce pro-inflammatory cytokine production associated with heart and kidney diseases; Inflammasome, a small molecule program to inhibit 1L-1 ß production; and OPN-401 peptide for disabling TLR signalling pathways involved in acute and chronic inflammatory diseases. Its products also include OPN-302, a soluble protein antagonist; OPN-501 small molecule chemistry platform and oral prodrug for the treatment of ulcerative colitis; and OpsoVacTM, a novel TLR pl...
The Trinity Centre for Health Sciences
Institute of Molecular Medicine
St James's Hospital
Founded in 2004
Key Executives for Opsona Therapeutics Ltd.
Co-Founder and Member of Scientific Advisory Board
Co-Founder and Scientific Advisor
Compensation as of Fiscal Year 2014.
Opsona Therapeutics Ltd. Key Developments
Opsona Therapeutics Ltd. Presents at BioEquity Europe 2014, May-21-2014 02:20 PM
May 18 14
Opsona Therapeutics Ltd. Presents at BioEquity Europe 2014, May-21-2014 02:20 PM. Venue: Hilton Amsterdam Hotel, Amsterdam, Netherlands.
Opsona Presents at BIO Asia International Conference, Apr-08-2014 01:30 PM
Apr 9 14
Opsona Presents at BIO Asia International Conference, Apr-08-2014 01:30 PM. Venue: Grand Hyatt, Tokyo, Tokyo, Japan.
Opsona Therapeutics Ltd. Presents at BioTrinity 2014 - European Biopartnering and Investment Conference, May-12-2014
Mar 21 14
Opsona Therapeutics Ltd. Presents at BioTrinity 2014 - European Biopartnering and Investment Conference, May-12-2014 . Venue: London, United Kingdom.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries